This Accepted Author Manuscript (AAM) is copyrighted and published by Elsevier. It is posted here by agreement between Elsevier and the University of Turin. Changes resulting from the publishing process - such as editing, corrections, structural formatting, and other quality control mechanisms - may not be reflected in this version of the text. The definitive version of the text was subsequently published in [Lancet. 2015 Jul 4;386(9988):27. doi: 10.1016/S0140-6736(15)61198-9].

You may download, copy and otherwise use the AAM for non-commercial purposes provided that your license is limited by the following restrictions:

(1) You may use this AAM for non-commercial purposes only under the terms of the CC-BY-NC-ND license.

(2) The integrity of the work and identification of the author, copyright owner, and publisher must be preserved in any copy.

(3) You must attribute this AAM in the following format: Creative Commons BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en), doi: 10.1016/S0140-6736(15)61198-9
Obeticholic acid: an effective treatment for diabetic patients with non-alcoholic steatohepatitis?

RUNNING TITLE: OCA and NASH

Giovanni Musso¹ M.D., Maurizio Cassader² Ph.D. Roberto Gambino² Ph.D.

¹Gradenigo Hospital, Italy
²Department of Medical Sciences, University of Turin, Italy

Corresponding author:
Giovanni Musso
Gradenigo Hospital
Corso Regina Margherita 8,
10132 Torino, Italy.
Phone: +39-11-3475944237
Fax: +39118151320
E-mail: giovanni_musso@yahoo.it

Word count: 399

KEY WORDS: NASH, OCA, FXR
To the Editor:

we read with interest the results of the FLINT trial, evaluating the effect of obeticholic acid (OCA) on liver histology in non-alcoholic steatohepatitis (NASH)\(^1\).

A remarkable yet overlooked result of this trial was the different histological response between diabetic and non-diabetic participants: among the former, liver histology improved in 53% patients with OCA vs. 19% on placebo (OR for improvement with OCA: 4.6, 95%CI=2.0-10.6, \(p=0.0003\)), while in non-diabetic patients, liver histology improved in 37% patients with OCA vs. 23% with placebo (OR: 2.0, 95%CI=0.8-4.7, \(p=0.12\)).

The impact of glucose intolerance on histological response to OCA was evident also across progressive stages of pancreatic \(\beta\)-cell dysfunction, as estimated by HOMA B-cell index (online Appendix Table S2)\(^1\).

Beside the FLINT, only another randomized trial, enrolling diabetic patients, evaluated OCA in non-alcoholic fatty liver (NAFLD)\(^2\). Therefore current evidence for effectiveness of farnesoid X receptor (FXR) agonists is lacking in non-diabetic individuals, a substantial proportion of NASH population.

Additionally, consistent with other randomized trials in NASH, the percentage of responders approached 50% in the FLINT, leaving a substantial proportion of patients without an effective treatment\(^3\). NASH is an heterogeneous conditions and diverse mechanisms of liver injury likely operate in different patient populations to promote liver disease progression. In humans, altered bile acid metabolism, which represents the rationale for using semi-synthetic bile acids, has been more convincingly demonstrated in diabetic that in non-diabetic individuals\(^4\), thereby potentially explaining the lack of response to OCA among non-diabetic individuals in the FLINT. Hence, further assessment of FXR agonists in nondiabetic NASH is mandatory, and an approach tailored to individual metabolic profile may be required to tackle NASH epidemic.
ACKNOWLEDGEMENTS

Author Contributions.

Giovanni Musso: conceived the article, undertook literature search and acquired data, critically analyzed the results, drafted the article, gave final approval

Giovanni Musso, as the corresponding author, had full access to all the data and takes final responsibility for the decision to submit for publication.

Maurizio Cassader: undertook literature search and acquired data, critically analyzed the results, contributed to draft of the article, gave final approval

Roberto Gambino: undertook literature search and acquired data, critically analyzed the results, contributed to draft of the article, gave final approval

Conflicts of interest.

Giovanni Musso has no present or past conflict of interest or financial relationship to disclose. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Roberto Gambino has no present or past conflict of interest or financial relationship to disclose. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Maurizio Cassader has no present or past conflict of interest or financial relationship to disclose. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Funding source. This manuscript was written without any funding source, nor has any author received payment from any pharmaceutical company or other agency to write this article.
REFERENCES


